{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:24:49Z","timestamp":1793651089366,"version":"4.5.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The objective of this study was to compare the incidence rates (IRs) of infectious diseases, major adverse cardiovascular events (MACEs), and malignancies in RA patients treated with tofacitinib, baricitinib or a TNF inhibitor.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively analysed the cases of 499 RA patients treated with tofacitinib (n\u2009=\u2009192), baricitinib (n\u2009=\u2009104), or a TNF inhibitor (n\u2009=\u2009203). We determined the IRs of infectious diseases and the standardized incidence ratio (SIR) of malignancies and investigated factors related to infectious diseases. After adjusting the clinical characteristic imbalance by propensity score weighting, we compared the incidence of adverse events between the Janus kinase (JAK)-inhibitor and TNF-inhibitor groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The observational period was 959.7 patient-years (PY), and the median observational period was 1.3\u2009years. The IRs within the JAK-inhibitor treatment group were: serious infectious diseases other than herpes zoster (HZ), 8.36\/100\u2009PY; HZ, 13.00\/100\u2009PY. Multivariable Cox regression analyses revealed independent risk factors: the glucocorticoid dose in serious infectious diseases other than HZ, and older age in HZ. Two MACEs and 11 malignancies were identified in JAK-inhibitor\u2013treated patients. The overall malignancy SIR was (non-significantly) higher than that of the general population (1.61\/100\u2009PY, 95% CI: 0.80, 2.88). The IR of HZ in the JAK-inhibitor\u2013treated group was significantly higher than the TNF-inhibitor-treated group, but there were no significant differences in the IRs of other adverse events between the JAK-inhibitor\u2013treated group and the TNF-inhibitor\u2013treated group, or between the treatment groups of the two JAK inhibitors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The infectious disease IR in RA was comparable between tofacitinib and baricitinib, but the IR for HZ in these treatment groups was high compared with that in the TNF inhibitor treatment group. The malignancy rate in the JAK-inhibitor-treated group was high but not significantly different from that of the general population or that of the TNF-inhibitor\u2013treated group.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead079","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T13:44:59Z","timestamp":1676555099000},"page":"3358-3365","source":"Crossref","is-referenced-by-count":32,"title":["Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2459-7214","authenticated-orcid":false,"given":"Tomohisa","family":"Uchida","sequence":"first","affiliation":[{"name":"Department of Rheumatology, National Hospital Organization Ureshino Medical Center , Ureshino, Japan"},{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-0757","authenticated-orcid":false,"given":"Naoki","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Fukui","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki, Japan"},{"name":"Department of General Medicine, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5340-6851","authenticated-orcid":false,"given":"Shimpei","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital , Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Aramaki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hakujujikai Sasebo Chuo Hospital , Sasebo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Shomura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, National Hospital Organization Ureshino Medical Center , Ureshino, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Aratake","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, National Hospital Organization Ureshino Medical Center , Ureshino, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Eguchi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hakujujikai Sasebo Chuo Hospital , Sasebo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitaka","family":"Ueki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hakujujikai Sasebo Chuo Hospital , Sasebo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"2023100322111827200_kead079-B1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"2023100322111827200_kead079-B2","first-page":"4","article-title":"Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence","volume":"81","author":"Cohen","year":"2008","journal-title":"J Rheumatol Suppl"},{"key":"2023100322111827200_kead079-B3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1503\/cmaj.091391","article-title":"A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview","volume":"181","author":"Singh","year":"2009","journal-title":"CMAJ"},{"key":"2023100322111827200_kead079-B4","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58(Suppl 1)","author":"Harigai","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2023100322111827200_kead079-B5","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2023100322111827200_kead079-B6","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023100322111827200_kead079-B7","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023100322111827200_kead079-B8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2023100322111827200_kead079-B9","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2023100322111827200_kead079-B10","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"2023100322111827200_kead079-B11","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3899\/jrheum.140533","article-title":"Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population","volume":"42","author":"Hashimoto","year":"2015","journal-title":"J Rheumatol"},{"key":"2023100322111827200_kead079-B12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3109\/14397595.2016.1141740","article-title":"Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: a nationwide cohort study in Japan","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2023100322111827200_kead079-B13","author":"R Core Team","year":"2021"},{"key":"2023100322111827200_kead079-B14","author":"Miettinen","year":"2022"},{"key":"2023100322111827200_kead079-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v009.i08","article-title":"Analysis of complex survey samples","volume":"9","author":"Lumley","year":"2004","journal-title":"J Stat Softw"},{"key":"2023100322111827200_kead079-B16","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2023100322111827200_kead079-B17","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/acr.21928","article-title":"Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study","volume":"65","author":"Veetil","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023100322111827200_kead079-B18","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023100322111827200_kead079-B19","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2023100322111827200_kead079-B20","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes Zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023100322111827200_kead079-B21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","article-title":"Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023100322111827200_kead079-B22","first-page":"1408","article-title":"AB0495 Post-marketing surveillance of tofacitinib in Japanese patients with rheumatoid arthritis: an interim report of safety data","volume":"77","author":"Tamura","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023100322111827200_kead079-B23","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","article-title":"Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"66","author":"Cohen","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2023100322111827200_kead079-B24","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023100322111827200_kead079-B25","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023100322111827200_kead079-B26","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"2023100322111827200_kead079-B27","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.semarthrit.2021.03.015","article-title":"Rheumatoid arthritis and risk of lung cancer: meta-analysis and Mendelian randomization study","volume":"51","author":"Wu","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2023100322111827200_kead079-B28","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00296-010-1524-0","article-title":"Incidence of malignancy in Japanese patients with rheumatoid arthritis","volume":"31","author":"Yamada","year":"2011","journal-title":"Rheumatol Int"},{"key":"2023100322111827200_kead079-B29","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s10067-019-04882-x","article-title":"Lung cancer in rheumatoid arthritis. Is there a need for better risk assessment and screening?","volume":"39","author":"Fragoulis","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2023100322111827200_kead079-B30","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.55563\/clinexprheumatol\/h9tc57","article-title":"Rheumatoid arthritis\u2013associated interstitial lung disease: epidemiology, risk\/prognostic factors, and treatment landscape","volume":"39","author":"Fazeli","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2023100322111827200_kead079-B31","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1136\/annrheumdis-2020-219699","article-title":"Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score\u2013based inverse probability of treatment weighting","volume":"80","author":"Miyazaki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023100322111827200_kead079-B32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13075-021-02582-z","article-title":"Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis","volume":"23","author":"Iwamoto","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2023100322111827200_kead079-B33","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.lungcan.2004.07.998","article-title":"Tobacco smoking and cancer: a brief review of recent epidemiological evidence","volume":"45(Suppl 2)","author":"Sasco","year":"2004","journal-title":"Lung Cancer"},{"key":"2023100322111827200_kead079-B34","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.39098","article-title":"Disease activity in rheumatoid arthritis and the risk of cardiovascular events","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead079\/50516026\/kead079.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/10\/3358\/51841376\/kead079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/10\/3358\/51841376\/kead079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T22:12:16Z","timestamp":1696371136000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/10\/3358\/7043090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,2,16]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead079","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,2,16]]}}}